Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2019-11-13 Earnings Release
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
8-K Q3 2019 EARNINGS RELEASE
Earnings Release Classification · 95% confidence The document is a Form 8-K filed by Novus Therapeutics, Inc. dated November 13, 2019. It announces the company's financial results for the period ended September 30, 2019, and includes a press release as Exhibit 99.1. The text explicitly states this is a Current Report on Form 8-K, which is typically used for current event disclosures including earnings releases. The document is relatively short (4134 characters) and primarily contains the announcement of the earnings release rather than the full financial report itself. Therefore, this document is best classified as an Earnings Release (ER).
2019-11-13 English
10-Q
Interim / Quarterly Report 9M 2019
2019-11-13 English
FORM 4 SUBMISSION
Director's Dealing
2019-10-01 English
FORM 4 SUBMISSION
Director's Dealing
2019-10-01 English
FORM 4 SUBMISSION
Director's Dealing
2019-10-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 13, 2019. It announces the company's financial results for the period ended June 30, 2019, and includes a press release as an exhibit. The text explicitly states that the full text of the press release is furnished as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the results and provides the press release. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. The document length is 4095 characters, which is relatively short and consistent with an earnings release announcement rather than a full interim or annual report. Therefore, the appropriate classification is Earnings Release (ER).
2019-08-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.